And one of them is pharmaceutical giant Pfizer ( PFE +1.98%). Now, with a major step along the path to entering this ...

Johnson & Johnson’s JNJ stock has risen 16.7% in the past three months. A lot of this price increase is due to strong ...

(NYSE:PFE) is one of the stocks Jim Cramer recently shed light on. Cramer highlighted some of the stock’s possible catalysts, ...

Pfizer possesses several qualities that make it attractive when market volatility is high. The stock has a low forward earnings multiple and a higher -- yet still attractive -- EV-to-EBITDA ratio.

Fintel reports that on November 24, 2025, Guggenheim maintained coverage of Pfizer (NYSE:PFE) with a Buy recommendation.

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an ...

Pfizer-funded study finds a next-gen mRNA flu shot works better against current strains — but causes more short-term side ...

Summary • Pfizer’s stock rose by 2.5% to $25.01 following the acquisition of Metsera, Inc.• The acquisition aims to enhance ...

With the end of the pandemic, sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, declined from their peak. However, Pfizer’s non-COVID operational revenues are improving, driven by its ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Though healthcare stocks have been much more measured this year, there are bright spots there as well. The medical-device maker Medtronic (MDT) closed at its highest price since May 12, 2022, after ...

Pfizer offers strong dividends, solid cash flow coverage, discounted value and key risks from patent cliffs, pricing and ...